Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi Therapeutics (MGX) Change in Taxes (2023)

Metagenomi (MGX) has disclosed Change in Taxes for 1 consecutive years, with $1.1 million as the latest value for Q4 2023.

  • Quarterly Change in Taxes changed N/A to $1.1 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $552000.0 through Dec 2024, down 68.09% year-over-year, with the annual reading at -$3.3 million for FY2024, 288.79% down from the prior year.
  • Change in Taxes for Q4 2023 was $1.1 million at Metagenomi, up from -$546000.0 in the prior quarter.
  • The five-year high for Change in Taxes was $1.9 million in Q1 2023, with the low at -$759000.0 in Q2 2023.